Good morning, everyone, and how are you today? We are doing just fine, thank you, despite a steady downpour that is making for a soggy feeling at the Pharmalot campus. Nonetheless, our spirits are sunny. How so? We will remind you of a favorite saying of the Morning Mayor: Every brand new day should be unwrapped like a precious gift. So while you tug on the ribbon, we will brew another cup of stimulation and forage for items of interest. Speaking of which, here are a few. Hope your journey goes well and, as always, do keep in touch. …

GlaxoSmithKline (GSK) plans to team with some of the nation’s most prominent CRISPR researchers to use the gene-editing technology in a search for new drugs, establishing a new lab in San Francisco and spending up to $67 million over five years, STAT reports. Jennifer Doudna, the University of California, Berkeley, researcher who co-invented the CRISPR enzyme technology, will help lead the effort, along with Jonathan Weissman, a UC San Francisco researcher who has been using CRISPR to understand the function of individual human genes and how they work together.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

  • One might observe that Mr Trump would be wiser to reserve his role in any negotiations to be “The Closer” – but then again, if he owns the process of the deal, mayhaps he will be less likely to call it “terrible” at the final moment? We shall see.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy